双歧杆菌三联活菌胶囊对胆囊切除术后腹泻患者肠道菌群及sIgA水平的影响

目的探讨双歧杆菌三联活菌胶囊对胆囊切除术后腹泻患者肠道菌群及sIgA水平的影响。方法选取胆囊切除术后腹泻患者68例,分为观察组和对照组。两组患者均予以低脂饮食和止泻药等常规治疗。观察组患者予以口服双歧杆菌三联活菌胶囊420 mg,3次/d,连用4周。对照组除不口服双歧三联活菌肠溶胶囊外余治疗基本同观察组。观察两组患者治疗前后肠道菌群和sIgA水平的变化,并比较其临床疗效。结果治疗4周后,观察组患者双歧杆菌和乳酸杆菌数量较前明显上升,肠杆菌和肠球菌较前明显减少（P〈0.05）,而对照组治疗前后肠道菌群数量均无明显变化（P〉0.05）;两组患者肠道sIgA水平较前明显上升（P〈0.05或P〈0.01）,且观察组上升值明显大于对照组（P〈0.05）;同时观察组患者临床总有效率明显高于对照组（χ2=5.31,P〈0.05）。结论双歧杆菌三联活菌胶囊治疗胆囊切除术后腹泻的疗效确切,能调节患者肠道菌群失调,从而重建肠道微生态平衡,提高肠道免疫力,改善和保护肠道功能。     

复合益生菌活菌制剂对肝硬化患者肠道菌群的影响

目的:观察肝硬化患者口服三联活菌后肠道菌群、血氧及血浆内毒素的变化.方法:选择肠道菌群中具有代表性的细菌进行培养和计数.42例肝硬化患者给予三联活菌治疗21 d.测定治疗前后肠道菌群菌落计数、血氨(干片法)、血浆内毒素(改良鲎试验法).结果:与正常对照组相比,肝硬化组患者存在不同程度的肠道菌群失调,主要表现为双歧杆菌减少(10.12±0.71比9.27±1.25,P＜0.05).治疗后,双歧杆菌由9.27±1.25增至10.43±1.25,差异有显著性(P＜0.01).且血氨水平降低,并可降低肝硬化患者血浆内毒素水平[(109.21±12.23)pg/ml比(71.46±9.12)pg/ml,P＜0.05].结论:肝硬化患者存在肠道菌群失调.益生菌制剂可有效改善肝硬化患者肠道菌群失调,并降低血氨及血浆内毒素.     

肝硬化患者口服培菲康和妈咪爱对肠道菌群影响的研究

目的:研究肝硬化患者肠道菌群的特点,观察患者口服妈咪爱和培菲康前后肠道菌群、粪便pH及血氮水平的变化.方法:选择肠道菌群中具有代表性的细菌共4种进行培养和计数.选择20例正常人为对照组,计数肠道菌群中4种细菌的数量.40例肝硬化患者随机分成2组,分别给予培菲康(三联活菌)及妈咪爱(二联活菌)共治疗14 d.观察治疗前后肠道菌群落计数、粪便pH、血氨水平.结果:①肝硬化组患者存在不同程度的肠道菌群失调,主要表现为双歧杆菌减少(P＜0.05),而肠球菌、肠杆菌则显著增多(P＜0.01)②菌群失调的严重程度随患者肝功能严重程度而加重.③临床表现有腹泻的肝硬化患者,肠道总体菌量和厌氧菌数量均低于非腹泻患者,以双歧杆菌(P＜0.01)减少为著.④两种益生菌制剂均可提高肝硬化患者肠道双歧杆菌的数量(P＜0.05),并可降低血氨和粪便pH(P＜0.05).结论:①肝硬化组患者存在肠道菌群失调.②益生菌制剂均可有效改善肝硬化患者肠道菌群失调并可降低血氨和粪便pH.     

双歧三联活菌胶囊对结肠造口术后腹泻患者肠道菌群及肠黏膜屏障功能的影响

目的探讨双歧三联活菌胶囊对结肠造口术后腹泻患者肠道菌群及肠黏膜屏障功能的影响。方法选取外科门诊就诊结肠造口术后腹泻患者82例,随机分为观察组和对照组各41例。两组患者均予以口服补液盐、止泻药等常规治疗。观察组加用双歧三联活菌胶囊温水口服,630mg/次,2次/d,连用4周。于治疗前后观察两组患者肠道菌群数量及肠黏膜屏障功能指标的变化,并比较其临床效果。结果治疗4周后,两组患者双歧杆菌、乳杆菌数量及B/E比值上升,大肠埃希菌和肠球菌数量下降(P0.05),且观察组变化幅度更大;两组患者血清D-乳酸和二胺氧化酶(DAO)水平降低(P0.05或P0.01),且观察组下降幅度更大(P0.05);在总有效率上观察组较对照组更佳(P0.05)。结论双歧三联活菌胶囊治疗结肠造口术后腹泻患者效果较佳,机制与其能调节肠道微生态平衡紊乱,重建肠道微生态平衡,并能保护与修复肠黏膜屏障,减少其通透性,改善肠道功能密切相关。     

马来酸曲美布汀联合双歧三联活菌胶囊对糖尿病性腹泻患者肠道菌群的影响及疗效观察

目的探讨马来酸曲美布汀联合双歧三联活菌胶囊对糖尿病性腹泻(DD)患者肠道菌群的影响及疗效。方法将86例DD患者随机分为观察组和对照组。两组患者均予以饮食调整、控制血糖和胃肠解痉药等基础治疗。观察组予以双歧三联活菌胶囊(420mg,3次/d,温开水送服)联合马来酸曲美布汀(200mg,3次/d,口服)治疗,对照组予以单用的双歧三联活菌胶囊治疗,两组患者均连用8周。观察并比较两组患者治疗前后肠道菌群数量的变化,比较其临床疗效及药物不良反应。结果治疗8周后,两组患者双歧杆菌、乳酸杆菌数量均较前增加,肠杆菌、肠球菌和酵母菌数量较前减少(P0.05),且观察组变化更明显(P0.05);同时观察组患者临床总有效率(94.74%)较对照组(78.95%)更佳(χ2=4.15,P0.05)。观察组患者治疗中发生不良反应3例,对照组发生1例,症状较轻,两组比较差异无统计学意义(χ2=0.26,P0.05)。结论双歧三联活菌胶囊联合马来酸曲美布汀治疗DD的疗效确切,安全性较佳,能有效缓解其腹泻症状,作用机制与其能纠正肠道菌群紊乱密切相关。     

双歧三联活菌胶囊对腹泻型肠易激综合征患者肠道菌群的影响及疗效观察

目的探讨双歧三联活菌胶囊对腹泻型肠易激综合征（IBS—D）患者肠道菌群的影响及疗效观察。方法将IBS—D患者70例随机分为观察组和对照组。两组患者均予以凋整饮食、胃肠解痉药和止泻药等常规治疗。观察组患者予以口服双歧杆菌三联活菌胶囊420mg,3次／d．温开水送服,连用4周。观察两组患者治疗前后肠道菌群的变化,并比较其临床疗效。结果治疗4周后,观察组患者双歧杆菌、乳酸杆菌数量较前增加,肠杆菌、肠球菌、酵母菌数量较前减少（P〈0．05）,但对照组治疗前后无明显变化（P〉0．05）;同时观察组患者临床总有效率（94．29％）明显优于对照组（74．29％）（χ2=5．29,P〈0．05）。结论双歧二三联活菌胶囊治疗IBS—D疗效较好,作用于其能调节患者肠道菌群紊乱,重建肠道微生态平衡密切相关。     

双歧三联活菌胶囊联合美沙拉嗪对 溃疡性结肠炎患者肠道微生态影响

目的探讨双歧三联活菌胶囊联合美沙拉嗪肠溶片对溃疡性结肠炎(ulcerative colitis,UC)患者肠道微生态的影响。方法选取2015年1月至2017年4月我院内科门诊治疗的活动期轻中度UC患者78例,随机分为观察组和对照组。两组均给予口服美沙拉嗪肠溶片1.0 g/次,4次/d。观察组在此基础上加以双歧三联活菌胶囊420 mg/次,3次/d,口服,两组均连用8周。比较两组治疗前后肠道菌群中乳杆菌、双歧杆菌、大肠埃希菌数量的变化和双歧杆菌(B)与大肠埃希菌(E)的比值变化,并评估两组治疗后临床效果。结果治疗前两组乳杆菌、双歧杆菌与大肠埃希菌及B/E比值比较,差异无统计学意义(P0.05)。治疗8周后,两组双歧杆菌、乳杆菌数量及B/E比值明显上升(P0.01),大肠埃希菌数量下降(P0.05),但观察组变化幅度更大(P0.05),且总有效率较对照组更高(χ2=4.13,P0.05)。结论双歧三联活菌胶囊联合美沙拉嗪肠溶片可治疗UC,能调节肠道菌群紊乱,重建肠道微生态平衡。     

微生态制剂在早期结直肠癌根治术后的作用

目的探讨微生态制剂在早期结直肠癌(CRC)根治术后的作用,并为此类患者提供一种术后康复支持疗法。方法选取2017年6月-2019年6月于本院接受早期CRC根治术术后97例患者作为研究对象,采用随机数字表分为观察组50例和对照组47例。两组术后均接受常规治疗,观察组在对照组基础上接受双歧杆菌三联活菌胶囊治疗,比较两组治疗前后细胞免疫指标、肠道微生态复杂度及属水平相对丰度、肠道菌群OTU数量、肠道黏膜屏障功能。结果治疗后观察组NK细胞、CD3~+T、CD4~+T、CD4~+/CD8~+T均提高(P0.05),观察组CD8~+T治疗前后相近(P0.05);治疗后对照组上述指标与治疗前差异均无统计学意义(P0.05),观察组NK细胞、CD3~+T、CD4~+T、CD4~+/CD8~+T均高于对照组(P0.05);治疗后观察组Chao1指数、Shannon指数、肠道菌群OTU数均升高(P0.05),对照组Chao1指数、Shannon指数、肠道菌群OTU数量治疗前后差异均无统计学意义(P0.05);治疗后观察组Chao1指数、Shannon指数、肠道菌群OTU数量均高于对照组(P0.05);治疗后观察组大肠杆菌、肠球菌、葡萄球菌属水平相对丰度均下降(P0.05),对照组均升高(P0.05),且观察组均低于对照组(P0.05);治疗后观察组乳杆菌、双歧杆菌、梭菌、类杆菌、链球菌属水平相对丰度均升高(P0.05),对照组均下降(P0.05),且观察组均高于对照组(P0.05);治疗后观察组血浆D-乳酸、DAO、I-FABP、内毒素水平分别为(6.94±1.23)mg/L、(3.45±0.65)U/L、(43.95±7.99)μg/L、(4.48±0.85)U/L,均较治疗前下降(P0.05),对照组各项指标水平分别为(15.59±2.79)mg/L、(7.74±1.35)U/L、(74.21±13.82)μg/L、(8.68±1.65)U/L,均较治疗前升高(P0.05),治疗后观察组血浆D-乳酸、DAO、I-FABP、内毒素水平均降低(P0.05)。结论微生态制剂可有效改善早期CRC患者根治术后的细胞免疫水平,有效纠正早期CRC术后患者肠道菌群失调,增强早期CRC根治术后患者肠黏膜屏障功能。     

微生态制剂对慢性肝衰竭患者肠道菌群的影响

目的探讨微生态调节剂双歧杆菌三联活菌对慢性肝衰竭患者肠道菌群的影响。方法根据治疗方法不同将46例慢性肝衰竭患者随机分为治疗组和对照组各23例,两组均给予慢性肝衰竭常规治疗,治疗组在上述基础上给予双歧杆菌三联活菌胶囊,210mg／粒,每次2粒,2次／d,疗程2周。观察治疗前后两组患者的肠道菌群菌落计数变化及血清总胆红素（TBiL）、凝血酶原时间（PT）变化。结果两组患者在实验前肠道菌群、TBiL、PT比较差异均无统计学意义（P〉0．05）。治疗2周后,对照组患者治疗前后肠道菌群无明显变化（P〉0．05）,TBiL、PT有所下降但不显著,治疗组患者的肠球菌、双歧杆菌、乳杆菌以及酵母样真菌的菌落数均较治疗前明显增加,TBiL、PT较前明显好转（P〈0．05）。结论口服双歧杆菌三联活菌制剂可以促进慢性肝衰竭患者肠道正常菌群的恢复及改善肝功能。     

双歧三联活菌胶囊联合阿托伐他汀对高脂血症患者肠道乳酸杆菌数量的影响及疗效观察

目的探讨双歧三联活菌胶囊联合阿托伐他汀对高脂血症患者肠道乳酸杆菌数量的影响及疗效观察。方法选取心内科就诊治疗的高脂血症患者86例,随机将其分为观察组(n=43例)和对照组(n=43例)。观察组患者予以双歧三联活菌胶囊联合阿托伐他汀治疗8周,其中双歧三联活菌胶囊420 mg/次,3次/d;阿托伐他汀片10 mg/次,1次/d。对照组患者予以单纯的阿托伐他汀治疗,剂量、方法及疗程同观察组。观察并记录两组患者治疗前后血脂总胆固醇(TC)、甘油三脂(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平及肠道乳酸杆菌数量的变化。结果治疗8周后,两组患者TC、TG和LDL-C较前均有不同程度下降,HDL-C水平较前均有不同程度上升(P0.05),且观察组下降或上升幅度较对照组更明显(P0.05);同时两组患者肠道乳酸杆菌数量较前均有不同程度上升(P0.05),且观察组上升幅度较对照组更明显(P0.05)。结论双歧三联活菌胶囊联合阿托伐他汀治疗高脂血症能更明显降低TC、TG和LDL-C水平,升高HDL-C水平,具有良好的调脂效应,可能与其能调整肠道内的微生物菌群,大幅提升肠道乳酸杆菌数量密切相关。     

Interaction with AEG-1 and MDM2 is associated with glioma development and progression and correlates with poor prognosis

Glioma is the most common central nervous system tumor with poor prognosis. The AEG-1 (Astrocyte Elevated Gene 1) gene displays oncogenic characteristics, including proliferation, metastasis, chemoresistance, invasion, and evasion of apoptosis, and is strongly linked to the occurrence of glioma. Here, we elucidated the potential contribution of AEG-1 in human glioma pathogenesis. In glioma cells, AEG-1 could directly interact with Murine Double Minute-2 (MDM2) protein resulting in MDM2-p53-mediated cell proliferation and apoptosis. MDM2 is being revealed as an oncoprotein, which is involved in many human cancers progression. By immunohistochemical and a multivariate analysis, expressions of AEG-1 and MDM2 were elevated in glioma and high AEG-1 and MDM2 expressions were showed to be correlated with poor prognosis. AEG-1-MDM2 interaction prolonged stabilization of MDM2 where AEG-1 inhibited ubiquitination and subsequent proteasome-mediated degradation of MDM2 protein. Moreover, slicing AEG-1 blocked MDM2 expression and then impacted MDM2-p53 pathway that influenced cell proliferation and apoptosis. These findings uncover a novel AEG-1-MDM2 interplay by which AEG-1 augments glioma progression and reveal a viable potential therapy for the treatment of glioma patients.     

价格随供求变化的捕获问题

本文对开放式渔场建立了价格随供求而变化的捕获模型,对模型进行了详细的分析,并从生态学和经济学的角度对结果作了解释。为生物资源的实际管理提供了理论依据。     

Zinc complexes with tricarballylic acid and Lewis bases with zero- and two-dimensional structures

Three ternary zinc complexes of the open chain polycarboxylic acid, tricarballylic (1,2,3-propane-tricarboxylic) acid (PTCH₃) have been isolated and characterized with crystallographic and physicochemical techniques. [Zn(PTCH)(phen)(H₂O)]₂ · 4H₂O (1) (where phen = 1,10-phenanthroline) has a unique dinuclear structure, while [Zn(PTCH)(bpy)]_n · 3nH₂O (2) and [Zn(PTCH)(epy)]_n · 4nH₂O (3) (where bpy = 4,4′-bipyridine and epy = 1,2-bis(4-pyridine)ethane) have 2D polymeric structures. The bis-deprotonated ligand, in all three complexes, uses for coordination only two oxygen atoms, which belong to the same carboxylate in 1, and to two different carboxylates in 2 and 3.     

Adducts with haemoglobin and with DNA in epichlorohydrin-exposed rats

Epichlorohydrin (1-chloro-2,3-epoxypropane; ECH) is an important industrial chemical and a carcinogen in experimental animals. The main aims of the present study were to characterize the adduct formation in female Wistar rats and to identify adducts that could potentially be used in human biomonitoring studies. The total binding of radioactivity to haemoglobin in rats administered 0, 0. 11, 0.22, 0.43, or 0.97 mmol [3H]ECH/kg body weight by i.p. injection, and sacrificed 24 h after treatment, was linearly related to a dose up to 0.43 mmol/kg body weight. The binding at the highest dose was higher than predicted by extrapolation from lower doses, indicating saturation of a metabolic process for elimination of ECH. Ion-exchange chromatography of a globin hydrolysate showed one major radioactivity peak corresponding to S-(3-chloro-2-hydroxypropyl)cysteine. The half-life of this adduct was estimated as about 4 days by analysis of globin from rats administered 0.43 mmol/kg body weight and sacrificed after 1, 2 and 9 days. Crosslinking of the adduct, presumably with glutathione, appeared to be the predominant secondary reaction. Hydrolysis of N-(3-chloro-2-hydroxypropyl)valine, the primary reaction product of ECH with N-terminal valine, would give N-(2,3-dihydroxypropyl)valine. A sensitive gas chromatography/mass spectrometry method for the dihydroxypropyl adduct was used to follow its formation and removal after administration of nonlabelled ECH (0.11 mmol/kg body weight). The level of this adduct reached a maximum of about 20 pmol/g globin after a few weeks, corresponding to about 0.1% of the initial binding of ECH to globin. N-7-(3-Chloro-2-hydroxypropyl)guanine was detected in rats administered 0.97 mmol [3H]ECH/kg body weight and sacrificed 6 h after treatment. The adduct levels in haemoglobin and DNA were compared with previously reported adduct levels in male Fischer 344 rats exposed to propylene oxide. Despite its higher chemical reactivity, the capacity of ECH to alkylate macromolecules in vivo was found to be somewhat lower than that of propylene oxide.